17th EHFG Electing Health The Europe We Want!

Transcription

1 01 03 October th EHFG Electing Health The Europe We Want! For more information about the final programme, speakers or the EHFG conference please contact us directly! Follow us on our social media channels SAVE THE DATE! 18th EHFG: 30 September 02 October 2015

2 EHFG-FORUM 4 PERSONALISED MEDICINE 2020 A Hospital s Perspective Bad Gastein, Austria Antonio L. Andreu Instituto de Salud Carlos III

3 Majadahonda Campus Chamartín Campus

4 Barriers to access PM in Europe Big Data Awareness Training Patients Collaboration IT and interoperability Verification Translation Research Standards Regulation Reimbursement

5 Reaches the NHS s defining elements Regulatory Services Evaluation Reaches the three levels of activity Heath care Training and teaching Research Reaches the three frameworks of action Ministry of Health Regional Governments Hospitals

6 Implementation of PM needs

7

8 European platforms as a key element for the implementation of PM

9 Health Research Institutes as an aggregation model for speeding up translation BASIC RESEARCH CLINICAL EPIDEMIOLOGICAL RESEARCH HEALTH SERVICES AND PUBLIC HEALTH RESEARCH UNIVERSITY OPI (Public Research Organization) UNIVERSITY HOSPITAL PRIMARY CARE RESEARCH UNIT PUBLIC+PRIVATE CENTRE HEALTH ADMINISTRATION HEALTH RESEARCH INSTITUTE

10 BIODONOSTIA IDIS IBSAL IDIPAZ IIS PRINCESA I + 12 IRYCIS IIS GM IDISSC IIS FJD IIS PdH IBIS IMIBIC IRB LLEIDA IDIBAPS IDIBELL VHIR GTIP IMIM SAN PABLO INCLIVA IIS LA FE

11 Examples of specific instruments to foster PM in Health Research Institutes Integrated Projects of Excelence PhDs Health Research Institute Health-oriented Companies. (Partnership Public-Private Sector)

12 Model of Institutes and cooperative structures (CS) CS N1 N2 Nn INSTITUTES: Hospital University Public Research Institutions Public Private Center I 2 I 3 I 4 I n

13

14 Cardiology Genomics Endocrinology Imaging

15 Health Research Institute Health-Oriented Company PhD program

16 Funded Projects PM 2013 INNOVATIVE STRATEGIES TO SEEK NOVEL BIOMARKERS AND PREDICTIVE MODELS IN SOLID ORGAN TRANSPLANTATION: ESTABLISHING PERSONALIZED TRANSPLANT MEDICINE. TRANSLATING HYPOXIA RESEARCH TO A CLINICAL SETTING: O2 DEFICIENCY TOLERANCE, BRAIN DYSFUNCTION, INFECTION, AND CANCER MICROENVIRONMENT INTERACTIONS IN THE PATHOGENESIS OF LYMPHOID NEOPLASMS AND CHRONIC INFLAMMATORY DISORDERS. IDENTIFICATION OF BIOMARKERS AND DESIGN OF NEW THERAPEUTIC STRATEGIES A PILOT PROJECT FOR PERSONALIZED CANCER MEDICINE: ONCOPROFILE THE OBESITY PARADOX IN MULTIPLE PREVALENT DISEASES: A TRANSLATIONAL APPROACH. BLOOD-BASED CANCER DETECTION: DEVELOPMENT OF AN ECONOMICAL, SENSITIVE AND RAPID PAPER-BASED DEVICE TO DETECT CELL FREE NUCLEIC ACIDS COMPREHENSIVE, INTEGRATIVE AND GENOMIC APPROACH TO THE UNDERSTANDING AND TREATMENT OF CANCER AND LEUKEMIA DIABETESCANCERCONNECT:TARGETING COMMON INFLAMMATORY MARKERS AND SIGNALING PATHWAYS IN DIABETES MELLITUS AND CANCER. IMMUNOREGULATORY MOLECULES AS BIOMARKERS PREDICTING RESPONSE TO BIOLOGICAL THERAPIES AND DISEASE SEVERITY IN IMMUNE-MEDIATED INFLAMATORY DISORDERS. BIOIMID PROJECT PREVENTING CARDIOVASCULAR ISCHEMIC EVENTS AND ARRESTING THEIR CONSEQUENCES IN TYPE 2 DIABETIC POPULATION: A MULTIDISCIPLINARY CLINICAL AND EXPERIMENTAL APPROACH MODULATION OF CELLULAR MICRO RNAS AS A THERAPEUTIC STRATEGY FOR THE CURE OF HIV INFECTION

17 INTEGRATED PROJECTS OF EXCELENCE CALL FOR PROJECTS 2014 Requested Applications Total requested CANCER CARDIOVASCULAR DISEASES NEUROLOGICAL AND MENTAL DISEASES INFECTIOUS DISEASES AND AIDS CHRONIC, INFLAMMATORY, NEPHROLOGIC AND RESPIRATORY DISEASES ENDOCRINE, DIGESTIVE DISEASES AND SURGERY PEDIATRICS, PERINATAL MEDICINE, CONGENITAL ANOMALIES BIOTECHNOLOGY, BIOENGINEERING AND GENOMIC TECHNOLOGIES TOTAL ENDOCRINE, DIGESTIVE DISEASES AND SURGERY; 6,06% PEDIATRICS, PERINATAL MEDICINE, CONGENITAL ANOMALIES; 6,06% BIOTECHNOLOGY, BIOENGINEERING AND GENOMIC TECHNOLOGIES; 3,03% CANCER; 24,24% CHRONIC, INFLAMMATORY, NEPHROLOGIC AND RESPIRATORY DISEASES; 21,21% INFECTIOUS DISEASES AND AIDS; 6,06% NEUROLOGICAL AND MENTAL DISEASES; 15,15% CARDIOVASCULAR DISEASES; 18,18%